• Bhawana Sain Research Scholar, Arya College of Pharmacy, Kukas, Jaipur, India
  • Dr. Vandana Sharma Principal, Arya College of Pharmacy, Kukas, Jaipur, India
  • Ashok Kumar Sharma Professor, Arya College of pharmacy, Kukas, Jaipur, India
  • Mr. Rakesh Goyal Professor, Arya College of pharmacy, Kukas, Jaipur, India
  • Mr. Mukesh Sharma Professor, Arya College of pharmacy, Kukas, Jaipur, India




Dalafloxacin, Antibacterial, Bacterial Infections

Abstract [English]

Antibiotics (from ancient Greek αντιβιοτικά, antiviotika), also called antibacterials, are a type of antimicrobials drug used in the treatment and prevention of bacterial infections. Cellulitis is an infection that involves the outer layers of the skin. It is commonly caused by bacteria known as beta-hemolytic streptococcus or Staphylococcus aureus. You may experience pain, swelling, tenderness, warmth, and redness in the infected area. Complicate skin and soft tissue infections (SSTIs) are common for both outpatient and hospitalized patients and traditionally include various clinical symptoms ranging from minor superficial infections to necrotizing fasciitis with high rates of mortality. Delafloxacin (DLX) is a new FQ pending approval, which has shown a good in vitro and in vivo activity against major pathogens associated with ABSSSIs and CA-RTIs. It also shows good activity against a broad spectrum of microorganisms, including those resistant to other FQ, and stability against multiresistant strains.


Download data is not yet available.


Melinta Therapeutics, Inc. A comparative evaluation of the single-dose efficacy of oral delafloxacin versus the single-dose efficacy of an intramuscular injection of ceftriaxone in subjects with uncomplicated urogenital gonorrhea. Available from:

https://clinicaltrials.gov/ct2/show/NCT02015637. NML Identifier NCT02015637. Accessed March 15, 2017.

FDA Drug Safety Communication: FDA advises restricting fluoro¬quinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects than can occur together. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm500143.htm. Accessed March 13, 2017.

Longcor J, Hopkins S, Wikler M, Lawrence L. A phase 2 safety and effciacy study of oral delafloxacin in subjects with acute bacterial exac¬erbation of chronic bronchitis (ABECB). Presented at: ID Week; 2012; San Diego, CA. Available from:

https://idsa.confex.com/idsa/2012/webprogram/Paper37662. Accessed March 15, 2017.

Melinta Therapeutics, Inc. A phase 3, multicenter, randomized, double-blind, comparator-controlled study to evaluate the safety and efficacy of intravenous to oral delafloxacin in adult subjects with community-acquired bacterial pneumonia. Available from:

https://clinicaltrials.gov/ct2/show/NCT02679573. NML Identifier: NCT02679573. Accessed March 15, 2017.

Melinta Therapeutics, Inc. A phase 3, multicenter, randomized, double-blind, active controlled study to evaluate the efficacy + safety of IV + oral delafloxacin compared with vancomycin + aztreonam in patients with acute bacterial skin and skin structure infections. Available from: https://clinicaltrials.gov/ct2/show/NCT01984684. NML Identifier: NCT01984684. Accessed March 15, 2017.

Melinta Therapeutics, Inc. A phase 3, multicenter, randomized, double-blind, active-controlled study to evaluate the efficacy and safety of delafloxacin compared with vancomycin + aztreonam in patients with acute bacterial skin and skin structure infections. Available from: https://clinicaltrials.gov/ct2/show/NCT01811732. NML Identifier: NCT01811732. Accessed March 15, 2017.

Hoover R, Marbury TC, Preston RA, et al. Clinical pharmacology of delafloxacin in patients with hepatic impairment. J Clin Pharmacol. 2016; 57(3):328–335. DOI: https://doi.org/10.1002/jcph.817

WHO. Guidelines for the Ttreatment of Neisseria Gonorrhoeae. Geneva: WHO; 2016. ISBN-13:978-92-4-154969-1.

Röderova M, Halova D, Papousek I, et al. Characteristics of Quinolone Resistance in Escherichia coli Isolates from Humans, Animals, and the Environment in the Czech Republic. Front Microbiol. 2016; 7:2147.

Tayebi Z, Heidari H, Kazemian H, Ghafoori SM, Boroumandi S, Houri H. Comparison of quinolone and beta-lactam resistance among Escherichia coli strains isolated from urinary tract infections. Infez Med. 2016; 24(4):326–330.

Kocsis B, Domokos J, Szabo D. Chemical structure and pharmacokinet¬ics of novel quinolone agents represented by avarofloxacin, delafloxa¬cin, finafloxacin, zabofloxacin and nemonoxacin. Ann Clin Microbiol Antimicrob. 2016; 15(1):34. DOI: https://doi.org/10.1186/s12941-016-0150-4

Soge OO, Salipante SJ, No D, Duffy E, Roberts MC. In vitro activity of Delafloxacin against clinical Neisseria gonorrhoeae isolates and selection of gonococcal delafloxacin resistance. Antimicrob Agents Chemother. 2016; 60(5):3106–3111. DOI: https://doi.org/10.1128/AAC.02798-15

Hoover R, Hunt T, Benedict M, et al. Safety, tolerability and pharma¬cokinetic properties of intravenous delafloxacin after single and multiple doses in healthy volunteers. Clin Ther. 2016; 38(1):53–65. DOI: https://doi.org/10.1016/j.clinthera.2015.11.019

Hoover R, Hunt T, Benedict M, et al. Single and multiple ascending-dose studies of oral delafloxacin: effects of food, sex and age. Clin Ther. 2016; 38(1):39–52. DOI: https://doi.org/10.1016/j.clinthera.2015.10.016

Fuzi M. Dissimilar fitness associated with resistance to fluoroquinolones influences clonal dynamics of various multiresistant bacteria. Front Microbiol. 2016; 7:1017. DOI: https://doi.org/10.3389/fmicb.2016.01017

Thabit AK, Crandon JL, Nicolau DP. Pharmacodynamic and phar¬macokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens. Int J Antimicrob Agents. 2016;48(5):535–541. DOI: https://doi.org/10.1016/j.ijantimicag.2016.08.012

Lepak AJ, Andes DR. In vivo pharmacodynamic target assessment of delafloxacin against staphylococcus aureus, Streptococcus pneumonia and Klebsiella pneumonia in the murine lung infection model. Antimi¬crob Agents Chemother. 2016;60(8):4764–4769. DOI: https://doi.org/10.1128/AAC.00647-16


Bassetti M, Della Siega P, Pecori D, Scarparo C, Righi E. Delafloxacin for the treatment of respiratory and skin infections. Expert Opin Investig Drugs. 2015;24(3):433–442. DOI: https://doi.org/10.1517/13543784.2015.1005205


Unemo M. Current and future antimicrobial treatment of gonorrhoea – the rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infectious Diseases. 2015;15:364 DOI: https://doi.org/10.1186/s12879-015-1029-2


Crandon JL, Nicolau DP. Effects or Urine Matrix and pH on the Potency of Delafloxacin and Ciprofloxacin against Urogenic Escherichia coli and Klebsiella penuemoniae. J Urol. 2015; 194(2):563–570. DOI: https://doi.org/10.1016/j.juro.2015.01.094

Van Bambeke F. Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy. Future Microbiol. 2015;10(7):1111–1123. DOI: https://doi.org/10.2217/fmb.15.39

Amin AN, Cerceo EA, Deitelzweig SB, Pile JC, Rosenberg DJ, Sherman BM.Hospitalist perspective on the treatment of skin and soft tissue infections. Mayo Clin Proc. 2014;89(10):1436–1451. DOI: https://doi.org/10.1016/j.mayocp.2014.04.018

Soge OO, Roberts MC, Lenderman C, et al. Evaluation of In vitro activ¬ity of delafloxacin against contemporary Neisseria gonorrhoeae isolates. Presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 5–9;2014; CA, USA (Abstract C-1401).

Siala W, Mingeot-Leclercq MP, Tulkens PM, Hallin M, Denis O, Van Bambeke F. Comparison of the antibiotic activities of daptomy¬cin, vancomycin, and the investigational fluoroquinolone delafloxacin against biofilms from Staphylococcus aureus clinical isolates. Antimi¬crob Agents Chemother. 2014;58(11):6385–6397 DOI: https://doi.org/10.1128/AAC.03482-14

O’Riordan W, Mehra P, Manos P, Kingsley J, Lawrence L, Cammarata S. A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections. Int J Infect Dis. 2014; 30:67–73. DOI: https://doi.org/10.1016/j.ijid.2014.10.009

Bauer J, Siala W, Tulkens PM, Van Bambeke F. A combined pharma¬codynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Satphylococcus aureus biofilms. Antimicrob Agents Chemother. 2013; 57(6):2726–2737. DOI: https://doi.org/10.1128/AAC.00181-13

Hoover R, Lawrence L, Smith C, Longcor J. Pharmacokinetics (PK) of delafloxacin in patients with varying degrees of renal impairment. Presented at: 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). CO, USA, 10–13 September 2013 (Abstract A-017E).

Remy JM, Tow-keogh CA, McConnell TS, Dalton JM, Devito JA. Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization. J Antimicrob Chemother. 2012; 64(12):2814–2820. DOI: https://doi.org/10.1093/jac/dks307

Lawrence L, Hopkins S, Sahm D, et al. Characterization and In vitro Activ¬ity of delafloxacin (DLX) against isolates from a phase 2 study of acute bacterial skin and skin structure infections (ABSSSI). Presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 9–12; 2012; CA, USA (Abstract E-208).

Itani KMF, Merchant S, Lin SJ, Akhras K, Alandete JC, Hatoum HT. Outcomes and management costs in patients hospitalized for skin and skin-structure infections. Am J Infect Control. 2011; 39(1):42–49. DOI: https://doi.org/10.1016/j.ajic.2010.03.018

Metha SD, Maclean I, Ndinya-Achola JO, et al. Emergence of quinolone resistance and cephalosporin MIC creep in Neisseria gonorrhoeae Isolates from a cohort of young men in kisumu, Kenya, 2002 to 2009. Antimicrob Agents Chemother. 2011; 55(8):3882–3888. DOI: https://doi.org/10.1128/AAC.00155-11

Lemaire S, Tulkens PM, Van Bambeke F. Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-Gram-positive fluoroquinolones moxifloxacin and delafloxacin against S. aureus. Antimicrob Agents Chemother. 2011; 55(2):649–658. DOI: https://doi.org/10.1128/AAC.01201-10

Goldstein EJ, Solomkin JS, Citron DM, Alder JD. Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin. Clin Infect Dis. 2011; 53(11):1074–1080. DOI: https://doi.org/10.1093/cid/cir664

Edelsberg J, Taneja C, Zervos M, et al. Trends in US hospital admis¬sions for skin and soft tissue infections. Emerg Infect Dis. 2009; 15(9):1516–1518. DOI: https://doi.org/10.3201/eid1509.081228

Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48(1):1–12. DOI: https://doi.org/10.1086/595011

Nakamura T, Shimizu C, Kasahara M, et al. Monte Carlo simulation for evaluation of the efficacy of carbapenems and new quinolones against ESBL-producing Escherichia coli. J Infect Chermother. 2009; 15(1):13–17. DOI: https://doi.org/10.1007/s10156-008-0656-6

Burak E, Bortolon E, Molstad D, et al. Pharmacokinetics and pharma¬codynamics of delafloxacin in S. aureus murine thigh infection models. CA, USA, 12–15 September 2009 (Poster A1–1941).

Weiss G, Reimnitz P, Hampel B, et al. Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study). J Chemother. 2009; 21(2):170–180. DOI: https://doi.org/10.1179/joc.2009.21.2.170

Hatoum HT, Akhras KS, Lin SJ. The attributable clinical and eco¬nomic burden of skin and skin structure infections in hospitalized patients: a matched cohort study. Diagn Microbiol Infect Dis. 2009; 64(3):305–310. Stass H, Rink AD, Delesen H, Kubitza D, Vestweber KH. Pharma¬cokinetics and peritoneal penetration of moxifloxacin in peritonitis. J Antimicrob Chemother. 2006; 58(3):693–696. DOI: https://doi.org/10.1093/jac/dkl305

Malangoni MA, Song J, Herrington J, Choudhri S, Pertel P. Randomized controlled trial of moxifloxacin compared with piperacillin–tazobactam and amoxicillin–clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg. 2006; 244(2):2004–2211. DOI: https://doi.org/10.1097/01.sla.0000230024.84190.a8

Firsov AA, Alferova IV, Smirnova MV, Lubenko IY, Portnoy YA, Zinner SH. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and Levofloxacin with Streptococcus Pneumoniae in an in vitro dynamic model. Int J Antimicrob Agents. 2005; 25(5):409–413. DOI: https://doi.org/10.1016/j.ijantimicag.2005.02.004

Wagenlehner FM, Weidner W, Sörgel F, Nabe KG. The role of antibiotics in chronic bacterial prostatitis. Int J Antimicrob Agents. 2005; 26(1):1–7. Moczygemba LR, Frei CR, Burgess DS. Pharmacodynamic mod¬eling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases. Clin Ther. 2004;26(11):1800–1807. DOI: https://doi.org/10.1016/j.clinthera.2004.11.009

Harnett SJ, Fraise AP, Andrews JM, Jevons G, Brenwald NP, Wise R. Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492. J Antimicrob Chemother. 2004; 53(5):783–792. DOI: https://doi.org/10.1093/jac/dkh180

ZhaHammerschlag MR, Roblin PM. The in vitro activity of a new fluo¬roquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumonia. J Antimicrob Chemother. 2004; 54(1):281–282. DOI: https://doi.org/10.1093/jac/dkh304

Almer LS, Hoffrage JB, Keller EL, Flamm RK, Shortridge VD. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms. Antimicrob Agents Chemother. 2004; 48(7):2771–2777. DOI: https://doi.org/10.1128/AAC.48.7.2771-2777.2004

Zinner SH, Vostrov SN, Alferova IV, Lubenko IY, Portnoy YA, Firsov AA. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aerugi¬nosa in an in vitro dynamic model. Int J Antimicrob Agents. 2004; 24(2):173–177. DOI: https://doi.org/10.1016/j.ijantimicag.2004.02.026

Firsov AA, Vostrov SN, Lubenko IY, Arzamastsev AP, Portnoy YA, Zinner SH. ABT492 and levofloxacin: comparison of their pharma¬codynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model. J Antimicrob Chemother. 2004; 54(1):178–186. DOI: https://doi.org/10.1093/jac/dkh242

Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis. 2003; 36(5):592–598. DOI: https://doi.org/10.1086/367653

Goldstein EJC, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis. Antimicrob Agents Chemother. 2003; 47(9):3008–3011. DOI: https://doi.org/10.1128/AAC.47.9.3008-3011.2003

Nel GG, Palatnick L, Nichol KA, Low DE, Hoban DJ; CROSS Study Group. Antimicrobial resistance in Haemophilus influenza and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother. 2003; 47(6):1875–1881. DOI: https://doi.org/10.1128/AAC.47.6.1875-1881.2003

Waites KB, Crabb DM, Duffy LB. Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ure¬aplasmas. Antimicrob Agents Chemother. 2003; 47(12):3973–3975. DOI: https://doi.org/10.1128/AAC.47.12.3973-3975.2003

Nilius AM, Shen LL, Hensey-Rudolff D, et al. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob Agents Chemother. 2003; 47(10):3260–3269. DOI: https://doi.org/10.1128/AAC.47.10.3260-3269.2003

Charalabopoulos K, Karachalios G, Baltogiannis D, Charalabopoulos A, Giannakopoulos X, Sofikitis N. Penetration of antimicrobial agents into the prostate. Chemotherapy. 2003; 49(6):269–279. DOI: https://doi.org/10.1159/000074526

Doern GV, Heilmann KP, Huynh HK, Rhomberg PR, Coffman SL, Brueggemann AB. Antimicrobial resistance among clinical isolates of Streptococcus pneumonia in the United States during 1999–2000, including a comparison of resistance rates since 1994–1995. Antimicrob Agents Chemother. 2001;45(6):1721–1729. DOI: https://doi.org/10.1128/AAC.45.6.1721-1729.2001

Hoban Dj, Doern GV, Fluit AC, et al. Worldwide prevalence of antimi¬crobial resistance in Streptococcus pneumonia, Haemophilus influenza, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin Infect Dis. 2001; 32(Suppl 2):S81–S93. DOI: https://doi.org/10.1086/320181




How to Cite

Sain, B., Sharma, V., Kumar Sharma, A., Goyal, R., & Sharma, M. (2018). DALAFLOXACIN- ANTIBACTERIAL: A REVIEW. International Journal of Research -GRANTHAALAYAH, 6(1), 91–101. https://doi.org/10.29121/granthaalayah.v6.i1.2018.1597